

1	obeticholic acid	chronic liver diseases	Intercept Pharmaceuticals and Summitomo Dainippon Pharma	2.621
---	------------------	------------------------------	---	-------

2 Emtricitabine+tenofir

alafenamide(F/TAF)

HIV-1 infection Gilead sciences and Japan Tobacco 2.006 3

tenofir

alafenamide+emtricitabine+

rilpivirine(R/F/TAF)

HIV-1 infection Gilead sciences and Janseen R&D 1.572 4 MK-5172A HCV infectiom Merck and co 1.537 5 venetoclax
chronic lymphocitic leukemia Abbvie 1.477 6 Nuplazid Parkinson's disease psychosis ACADIA Pharmaceuticals

1.409

7uptravipulmonary arterial hypertensionNippon Shinyaku and Actellion1.268

The relationship between drug prices and the costs of development is expected to be a major focal point for drug companies, investors, regulators and politicians this year," said Mr hard Harrison, chief scientific officer, Intellectual Property & Science, Thomson Reuters. "With the rise of global healthcare costs, the need to demonstrate meaningful impact will be greater than ever for pharmaceutical companies. These seven drugs are likely to figure prominently in those discussions."

Having accurately anticipated that 11 new potential blockbuster drugs would enter the market in 2015 - all of which are still forecast to reach blockbuster status by 2019 (with the exception of Gardasil 9, for which forecasts were not available as of January 2016) - the Drugs to Watch report addresses a new line-up of significant therapeutics for the year ahead.

Thomson Reuters analysts utilized Cortellis Competitive Intelligence, the pharmaceutical industry's leading source for drug pipeline, deals, patents, and company content to forecast the new-to-market drugs expected to lead the pack in sales and potentially emerge as blockbusters (earning \$ 1 billion+) by 2020.